French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...

New research shows some gut bacteria mimic myelin, tricking immunity to attack nerves and worsen MS. Non-inflammatory ...

New research reveals a strong link between persistent brain inflammation and early brain shrinkage in children with MS. These ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the ...

Multiple Sclerosis Awareness Month highlights education, advocacy, research support, and ways to uplift the MS community throughout March.

The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

The over-the-counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the ...

Children with MS who have more paramagnetic rim lesions, or chronic inflammation, tend to show faster declines in brain ...

Tolebrutinib was one of three oral BTK inhibitors that Sanofi acquired as part of its $3.7 billion buyout of Principia ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...

So continues the rocky path for the drug, which Sanofi picked up in its $3.7 billion buyout of Principia Biopharma back in ...

Indiana Hoosiers quarterback Fernando Mendoza just won the highly coveted Heisman Trophy, and in his acceptance speech he ...